What was Mounjaro made for, and why does that matter now?

Was Mounjaro first made to treat diabetes or obesity?

Diabetes came first. Eli Lilly designed tirzepatide to improve glycaemic control in adults with type 2 diabetes by targeting two incretin receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Earlier GLP-1 medicines, such as the semaglutide in Wegovy, act on one of those pathways. Tirzepatide acts on both, which is why it is described as a dual-agonist and why its pharmacology was considered genuinely novel.

The SURPASS diabetes trial programme produced consistent, statistically significant reductions in HbA1c, but researchers and clinicians noticed something else: participants were losing substantially more body weight than had been seen with earlier GLP-1 medicines. That observation prompted Lilly to run the dedicated SURMOUNT weight-management programme, which enrolled thousands of adults with obesity. SURMOUNT-1 alone randomised 2,539 participants and reported average weight reductions of around 20–21% at the highest dose over 72 weeks, results that caught the attention of regulators worldwide. You can read more about tirzepatide's clinical profile in our full overview.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted Mounjaro its weight-management licence following that evidence base, and NICE formally recommended it for weight management in December 2024 (NICE technology appraisal TA1026). The diabetes licence came separately and remains in place. Both licences coexist; the same pen is dispensed for both indications, though the prescribing context and eligibility criteria differ.

How does the mechanism explain what Mounjaro was built to do?

The dual-receptor approach is not accidental. GIP and GLP-1 are hormones released from the gut after eating. They signal fullness, slow gastric emptying, and tell the pancreas to release insulin in response to a meal. By activating both receptors at once, tirzepatide sends a stronger and more sustained signal than either pathway produces alone. That is why appetite suppression tends to be pronounced, and why blood-sugar responses are more tightly controlled than with single-pathway predecessors.

For a closer look at the chemistry involved, our page on what Mounjaro is made of covers the molecular composition, and the page on what tirzepatide is made from explains how it is formulated for injection. The short version: tirzepatide is a synthetic peptide that mimics naturally occurring gut hormones, delivered once weekly via a pre-filled KwikPen. Most people keep the pen in the fridge door and set a weekly reminder; it slots into a routine quickly.

This dual action also explains the side-effect profile. Because both receptors influence gastric emptying, the most common effects are gastrointestinal: nausea, indigestion, changes in bowel habit. These typically ease within the first few weeks of a new dose. The NHS provides a thorough patient-level overview of tirzepatide's effects and side effects, and it is worth reading before starting treatment.

Who is Mounjaro's weight-management licence actually intended for?

The weight-management licence targets adults, not younger patients. Under-18s are not covered, and the medicine is not recommended during pregnancy, breastfeeding or when trying to conceive. For adults, the BMI thresholds are 30 or above for weight management on its own, or 27 or above where a weight-related condition is also present, things like high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance; eligibility is never determined by a single number.

NICE's recommendation for NHS use sits at a higher threshold (BMI 35 or above, with specific comorbidities) because it is rationing a publicly funded resource across a phased rollout. Private prescribing follows the licensed indication rather than the NICE criteria, which is why some people access Mounjaro privately before they would qualify through the NHS. Our weight-loss treatment overview sets out both routes plainly.

A prescriber assesses the whole clinical picture. BMI is the starting point, not the conclusion. Someone with a BMI of 28 and well-controlled blood pressure might not be suitable; someone with a BMI of 29 and obstructive sleep apnoea might be. That judgement belongs with the clinician, which is why Mounjaro is a prescription-only medicine and why a full clinical assessment precedes any legitimate supply. For background on who makes and regulates the medicine, the page on who manufactures Mounjaro covers Eli Lilly's role and the UK supply chain.

What does this history mean for someone considering it now?

Knowing that Mounjaro started as a diabetes medicine has a few practical implications. First, the evidence base is unusually large. Tirzepatide has been studied across both the SURPASS and SURMOUNT programmes, accumulating data from well over ten thousand participants across indications. That depth of evidence informed both the MHRA licence and the NICE appraisal, and it is why the clinical confidence behind the medicine is high.

Second, the diabetes licence means prescribers have extensive real-world experience with tirzepatide, including how it behaves at different doses, how side effects evolve, and which patients do best. That knowledge transfers directly into weight-management prescribing. Third, the dual-agonist mechanism (the thing that was novel enough to make Lilly pursue a separate weight-management programme) remains its key differentiator from the semaglutide-based options. A head-to-head trial (SURMOUNT-5, published in the New England Journal of Medicine in 2025) found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity.

If you would like to understand how that clinical evidence applies to your own situation, our clinical team carries out same-day prescription reviews. For context on what treatment costs as a private patient, our Mounjaro price comparison page explains the market honestly. Treatment is a clinical decision. Speak to our prescribers to find out whether Mounjaro is right for you.